Status:
COMPLETED
An Integrated Digital PROM-platform for Cancer Patients During the COVID-19 Pandemic
Lead Sponsor:
Jessa Hospital
Collaborating Sponsors:
Hasselt University
Conditions:
Covid19
Oncology
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
During the COVID-19 pandemic, patients with cancer are subject to multiple risks (e.g. frequent hospital visits, increased infection risk, more severe clinical course, discontinued cancer treatment et...
Detailed Description
General aim: The overall aim of this project is to prospectively evaluate the impact of a COVID-19 infection on the severity of the cancer therapy-related complications and the QoL of patients with ca...
Eligibility Criteria
Inclusion
- Diagnosed with any type of cancer (except breast cancer)
- Undergoing or starting chemotherapy with or without surgery
- Age ≥ 18 years
- Access to the online application via computer or smartphone
- Able to comply with the study protocol
- Able to sign written informed consent in the digital AWELL platform
- Provide a signed informed consent
Exclusion
- Diagnosed with breast cancer and undergoing chemotherapy (patients are already included in the healthcare path breast at Jessa Hospital)
- Undergoing other therapies (e.g. immunotherapy, radiotherapy, targeted therapy, hormonal therapy)
- Insufficient understanding of the Dutch language
- Severe cognitive impairment
Key Trial Info
Start Date :
August 3 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 22 2021
Estimated Enrollment :
43 Patients enrolled
Trial Details
Trial ID
NCT04816656
Start Date
August 3 2020
End Date
March 22 2021
Last Update
March 26 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Hasselt University
Hasselt, Limburg, Belgium, 3500
2
Jessa Ziekenhuis
Hasselt, Limburg, Belgium, 3500